Surface Oncology, Inc. (SURF) is a publicly traded company in the Unknown sector. Across all available filings, 30 corporate insiders have executed 109 transactions totaling $139.4M, demonstrating a bearish sentiment with -$54.4M in net insider flow. The most recent transaction on Sep 8, 2023 involved a transaction of 56,686 shares valued at $0.
No significant insider buying has been recorded for SURF in the recent period.
No significant insider selling has been recorded for SURF in the recent period.
Based on recent SEC filings, insider sentiment for SURF is bearish with an Insider Alignment Score of 30/100 and a net flow of -$54.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Surface Oncology, Inc. (SURF) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 30 insiders are actively trading SURF stock, having executed 109 transactions in the past 90 days. The most active insider is David S. Grayzel (Executive), who has made 5 transactions totaling $46.0M.
Get notified when executives and directors at SURF file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 8, 2023 | Oneill Alison | Executive | Disposition | 56,686 | $N/A | $0 | |
| Sep 8, 2023 | S. Grayzel David | Executive | Disposition | 2,945,453 | $N/A | $0 | |
| Sep 8, 2023 | W. Ross Robert | Executive | Disposition | 83,193 | $N/A | $0 | |
| Sep 8, 2023 | Goater Jeff | Executive | Disposition | 129,222 | $N/A | $0 | |
| Sep 8, 2023 | C. Rath Henry | Executive | Disposition | 44,971 | $N/A | $0 | |
| Sep 8, 2023 | Adams Chandra | Executive | Disposition | 23,884 | $N/A | $0 | |
| Sep 8, 2023 | Elliott Sigal Charles | Executive | Disposition | 45,453 | $N/A | $0 | |
| Sep 8, 2023 | Fees Jessica | Executive | Disposition | 101,915 | $N/A | $0 | |
| Sep 8, 2023 | J. Palombella Vito | Executive | Disposition | 87,212 | $N/A | $0 | |
| Aug 1, 2023 | W. Ross Robert | Executive | Sale | 16,713 | $0.94 | $15.7K | |
| Aug 1, 2023 | Fees Jessica | Executive | Sale | 9,434 | $0.94 | $8.9K | |
| Aug 1, 2023 | Adams Chandra | Executive | Sale | 3,901 | $0.94 | $3.7K | |
| Aug 1, 2023 | Oneill Alison | Executive | Sale | 7,042 | $0.94 | $6.6K | |
| Aug 3, 2022 | J. Palombella Vito | Executive | Sale | 4,463 | $1.72 | $7.7K | |
| Aug 3, 2022 | Fees Jessica | Executive | Sale | 5,980 | $1.72 | $10.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 35 | $96.9M | 68.9% |
Purchase(P) | 16 | $42.5M | 30.2% |
Exercise(M) | 16 | $1.2M | 0.8% |
Award(A) | 13 | $8.5K | 0.0% |
Disposition(D) | 9 | $0 | 0.0% |
Conversion(C) | 20 | $0 | 0.0% |
Insider selling pressure at Surface Oncology, Inc. has increased, with 30 insiders executing 109 transactions across all time. Total sales of $96.9M significantly outpace purchases of $42.5M, resulting in a net outflow of $54.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.